Tasha Tsao

Tasha Tsao

Auto-generated profile, based on publicly available information

Tasha Tsao

Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YZYang Zhou
Yang Zhou
Tiffany HusmanTiffany Husman
Tiffany Husman
Xinjian CenXinjian Cen
Xinjian Cen
TTTasha Tsao
Tasha Tsao
JBJames W Brown
James W Brown
LYLili Yang
Lili Yang
Cell-based cancer immunotherapy, such as chimeric antigen receptor (CAR) engineered T and natural killer (NK) cell therapies, has become a revolutionary new pillar in cancer treatment. Interleukin 15 (IL-15), a potent immunostimulatory cytokine that potentiates T and NK cell immune responses, has demonstrated the reliability and potency to potentially improve the therapeutic efficacy of current cell therapy. Structurally similar to interleukin 2 (IL-2), IL-15 supports the persistence of CD8+ memory T cells while inhibiting IL-2-induced T cell death that better maintains long-term anti-tumor immunity. In this review, we describe the biology of IL-15, studies on administrating IL-15 and/or its derivatives as immunotherapeutic agents, and IL-15-armored immune cells in adoptive cell therapy. We also discuss the advantages and challenges of incorporating IL-15 in cell-based immunotherapy and provide directions for future investigation.